Nucleoside analogue delivery systems in cancer therapy
Nucleoside analogues (NAs) are important agents in the treatment of hematological malignancies. They are prodrugs that require activation by phosphorylation. Their rapid catabolism, cell resistance and overdistribution in the body jeopardize nucleoside analogue chemotherapy. Accordingly, therapeutic...
Gespeichert in:
| Veröffentlicht in: | Expert opinion on drug delivery 2007-09, Vol.4 (5), p.513-531 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 531 |
|---|---|
| container_issue | 5 |
| container_start_page | 513 |
| container_title | Expert opinion on drug delivery |
| container_volume | 4 |
| creator | Diab, Roudayna Degobert, Ghania Hamoudeh, Misara Dumontet, Charles Fessi, Hatem |
| description | Nucleoside analogues (NAs) are important agents in the treatment of hematological malignancies. They are prodrugs that require activation by phosphorylation. Their rapid catabolism, cell resistance and overdistribution in the body jeopardize nucleoside analogue chemotherapy. Accordingly, therapeutic doses of NAs are particularly high and regularly have to be increased, resulting in severe toxicity and narrow therapeutic index. The major challenge is to concentrate the drug at the tumour site, avoiding its distribution to normal tissues. New drug carriers and biomaterials are being developed to overcome some of these obstacles. This review highlights novel NA delivery systems and discusses new technologies that could improve NA cancer therapy. |
| doi_str_mv | 10.1517/17425247.4.5.513 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_02059602v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20350481</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-e0713487245158fe8a2411f433af8f0b7a8ed7696db69c61c3f87e85cd4d8aa73</originalsourceid><addsrcrecordid>eNp9kUtP3DAURq0KVB7tviuUFVIXGfyMPe1qhApUGsGmXVt3nOtOkBMPdgLKv2-GmRaxgJWt6_N9ujom5AujM6aYvmBacsWlnsmZmikmPpDjaSRLrebi4PnOy-37ETnJ-Z5SUWnKPpIjpo2hXMtjUt0OLmDMTY0FdBDinwGLGkPziGks8ph7bHPRdIWDzmEq-jUm2IyfyKGHkPHz_jwlv69-_Lq8KZd31z8vF8vSyUr1JVLNhDSaS8WU8WiAS8a8FAK88XSlwWCtq3lVr6q5q5gT3mg0ytWyNgBanJKvu941BLtJTQtptBEae7NY2u2McqrmFeWPbGLPd-wmxYcBc2_bJjsMATqMQ7acCkWl2YJ0B7oUc07o_zczarde7T-vVlplJ69T5GzfPaxarF8Ce5ET8H0HNJ2PqYWnmEJtexhDTD5N7ppsxTv1316l1wihXztIaO_jkKZ_yW_v9hdwypdk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20350481</pqid></control><display><type>article</type><title>Nucleoside analogue delivery systems in cancer therapy</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Diab, Roudayna ; Degobert, Ghania ; Hamoudeh, Misara ; Dumontet, Charles ; Fessi, Hatem</creator><creatorcontrib>Diab, Roudayna ; Degobert, Ghania ; Hamoudeh, Misara ; Dumontet, Charles ; Fessi, Hatem</creatorcontrib><description>Nucleoside analogues (NAs) are important agents in the treatment of hematological malignancies. They are prodrugs that require activation by phosphorylation. Their rapid catabolism, cell resistance and overdistribution in the body jeopardize nucleoside analogue chemotherapy. Accordingly, therapeutic doses of NAs are particularly high and regularly have to be increased, resulting in severe toxicity and narrow therapeutic index. The major challenge is to concentrate the drug at the tumour site, avoiding its distribution to normal tissues. New drug carriers and biomaterials are being developed to overcome some of these obstacles. This review highlights novel NA delivery systems and discusses new technologies that could improve NA cancer therapy.</description><identifier>ISSN: 1742-5247</identifier><identifier>EISSN: 1744-7593</identifier><identifier>EISSN: 1743-5247</identifier><identifier>DOI: 10.1517/17425247.4.5.513</identifier><identifier>PMID: 17880274</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacokinetics ; dendrimers ; DepoFoam ; Dose-Response Relationship, Drug ; Drug Carriers ; Drug Delivery Systems ; Drug Resistance, Neoplasm ; Hematologic Neoplasms - drug therapy ; Humans ; inclusion complexes ; Life Sciences ; liposomes ; microparticles ; nanoparticles ; Nucleosides - administration & dosage ; Nucleosides - chemistry ; Nucleosides - pharmacokinetics ; particles ; Pharmaceutical sciences ; polymeric micelles ; polyplex nanogels ; Prodrugs ; Stealth ; Technology, Pharmaceutical ; vesicular phospholipid gel</subject><ispartof>Expert opinion on drug delivery, 2007-09, Vol.4 (5), p.513-531</ispartof><rights>Informa UK Ltd 2007</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c465t-e0713487245158fe8a2411f433af8f0b7a8ed7696db69c61c3f87e85cd4d8aa73</citedby><cites>FETCH-LOGICAL-c465t-e0713487245158fe8a2411f433af8f0b7a8ed7696db69c61c3f87e85cd4d8aa73</cites><orcidid>0000-0002-5389-6360 ; 0000-0001-9223-0353 ; 0000-0003-1875-134X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1517/17425247.4.5.513$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1517/17425247.4.5.513$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,59646,59752,60435,60541,61220,61255,61401,61436</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17880274$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-02059602$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Diab, Roudayna</creatorcontrib><creatorcontrib>Degobert, Ghania</creatorcontrib><creatorcontrib>Hamoudeh, Misara</creatorcontrib><creatorcontrib>Dumontet, Charles</creatorcontrib><creatorcontrib>Fessi, Hatem</creatorcontrib><title>Nucleoside analogue delivery systems in cancer therapy</title><title>Expert opinion on drug delivery</title><addtitle>Expert Opin Drug Deliv</addtitle><description>Nucleoside analogues (NAs) are important agents in the treatment of hematological malignancies. They are prodrugs that require activation by phosphorylation. Their rapid catabolism, cell resistance and overdistribution in the body jeopardize nucleoside analogue chemotherapy. Accordingly, therapeutic doses of NAs are particularly high and regularly have to be increased, resulting in severe toxicity and narrow therapeutic index. The major challenge is to concentrate the drug at the tumour site, avoiding its distribution to normal tissues. New drug carriers and biomaterials are being developed to overcome some of these obstacles. This review highlights novel NA delivery systems and discusses new technologies that could improve NA cancer therapy.</description><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>dendrimers</subject><subject>DepoFoam</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Carriers</subject><subject>Drug Delivery Systems</subject><subject>Drug Resistance, Neoplasm</subject><subject>Hematologic Neoplasms - drug therapy</subject><subject>Humans</subject><subject>inclusion complexes</subject><subject>Life Sciences</subject><subject>liposomes</subject><subject>microparticles</subject><subject>nanoparticles</subject><subject>Nucleosides - administration & dosage</subject><subject>Nucleosides - chemistry</subject><subject>Nucleosides - pharmacokinetics</subject><subject>particles</subject><subject>Pharmaceutical sciences</subject><subject>polymeric micelles</subject><subject>polyplex nanogels</subject><subject>Prodrugs</subject><subject>Stealth</subject><subject>Technology, Pharmaceutical</subject><subject>vesicular phospholipid gel</subject><issn>1742-5247</issn><issn>1744-7593</issn><issn>1743-5247</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtP3DAURq0KVB7tviuUFVIXGfyMPe1qhApUGsGmXVt3nOtOkBMPdgLKv2-GmRaxgJWt6_N9ujom5AujM6aYvmBacsWlnsmZmikmPpDjaSRLrebi4PnOy-37ETnJ-Z5SUWnKPpIjpo2hXMtjUt0OLmDMTY0FdBDinwGLGkPziGks8ph7bHPRdIWDzmEq-jUm2IyfyKGHkPHz_jwlv69-_Lq8KZd31z8vF8vSyUr1JVLNhDSaS8WU8WiAS8a8FAK88XSlwWCtq3lVr6q5q5gT3mg0ytWyNgBanJKvu941BLtJTQtptBEae7NY2u2McqrmFeWPbGLPd-wmxYcBc2_bJjsMATqMQ7acCkWl2YJ0B7oUc07o_zczarde7T-vVlplJ69T5GzfPaxarF8Ce5ET8H0HNJ2PqYWnmEJtexhDTD5N7ppsxTv1316l1wihXztIaO_jkKZ_yW_v9hdwypdk</recordid><startdate>20070901</startdate><enddate>20070901</enddate><creator>Diab, Roudayna</creator><creator>Degobert, Ghania</creator><creator>Hamoudeh, Misara</creator><creator>Dumontet, Charles</creator><creator>Fessi, Hatem</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0002-5389-6360</orcidid><orcidid>https://orcid.org/0000-0001-9223-0353</orcidid><orcidid>https://orcid.org/0000-0003-1875-134X</orcidid></search><sort><creationdate>20070901</creationdate><title>Nucleoside analogue delivery systems in cancer therapy</title><author>Diab, Roudayna ; Degobert, Ghania ; Hamoudeh, Misara ; Dumontet, Charles ; Fessi, Hatem</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-e0713487245158fe8a2411f433af8f0b7a8ed7696db69c61c3f87e85cd4d8aa73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>dendrimers</topic><topic>DepoFoam</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Carriers</topic><topic>Drug Delivery Systems</topic><topic>Drug Resistance, Neoplasm</topic><topic>Hematologic Neoplasms - drug therapy</topic><topic>Humans</topic><topic>inclusion complexes</topic><topic>Life Sciences</topic><topic>liposomes</topic><topic>microparticles</topic><topic>nanoparticles</topic><topic>Nucleosides - administration & dosage</topic><topic>Nucleosides - chemistry</topic><topic>Nucleosides - pharmacokinetics</topic><topic>particles</topic><topic>Pharmaceutical sciences</topic><topic>polymeric micelles</topic><topic>polyplex nanogels</topic><topic>Prodrugs</topic><topic>Stealth</topic><topic>Technology, Pharmaceutical</topic><topic>vesicular phospholipid gel</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Diab, Roudayna</creatorcontrib><creatorcontrib>Degobert, Ghania</creatorcontrib><creatorcontrib>Hamoudeh, Misara</creatorcontrib><creatorcontrib>Dumontet, Charles</creatorcontrib><creatorcontrib>Fessi, Hatem</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Expert opinion on drug delivery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Diab, Roudayna</au><au>Degobert, Ghania</au><au>Hamoudeh, Misara</au><au>Dumontet, Charles</au><au>Fessi, Hatem</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nucleoside analogue delivery systems in cancer therapy</atitle><jtitle>Expert opinion on drug delivery</jtitle><addtitle>Expert Opin Drug Deliv</addtitle><date>2007-09-01</date><risdate>2007</risdate><volume>4</volume><issue>5</issue><spage>513</spage><epage>531</epage><pages>513-531</pages><issn>1742-5247</issn><eissn>1744-7593</eissn><eissn>1743-5247</eissn><abstract>Nucleoside analogues (NAs) are important agents in the treatment of hematological malignancies. They are prodrugs that require activation by phosphorylation. Their rapid catabolism, cell resistance and overdistribution in the body jeopardize nucleoside analogue chemotherapy. Accordingly, therapeutic doses of NAs are particularly high and regularly have to be increased, resulting in severe toxicity and narrow therapeutic index. The major challenge is to concentrate the drug at the tumour site, avoiding its distribution to normal tissues. New drug carriers and biomaterials are being developed to overcome some of these obstacles. This review highlights novel NA delivery systems and discusses new technologies that could improve NA cancer therapy.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>17880274</pmid><doi>10.1517/17425247.4.5.513</doi><tpages>19</tpages><orcidid>https://orcid.org/0000-0002-5389-6360</orcidid><orcidid>https://orcid.org/0000-0001-9223-0353</orcidid><orcidid>https://orcid.org/0000-0003-1875-134X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1742-5247 |
| ispartof | Expert opinion on drug delivery, 2007-09, Vol.4 (5), p.513-531 |
| issn | 1742-5247 1744-7593 1743-5247 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_02059602v1 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacokinetics dendrimers DepoFoam Dose-Response Relationship, Drug Drug Carriers Drug Delivery Systems Drug Resistance, Neoplasm Hematologic Neoplasms - drug therapy Humans inclusion complexes Life Sciences liposomes microparticles nanoparticles Nucleosides - administration & dosage Nucleosides - chemistry Nucleosides - pharmacokinetics particles Pharmaceutical sciences polymeric micelles polyplex nanogels Prodrugs Stealth Technology, Pharmaceutical vesicular phospholipid gel |
| title | Nucleoside analogue delivery systems in cancer therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T13%3A35%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nucleoside%20analogue%20delivery%20systems%20in%20cancer%20therapy&rft.jtitle=Expert%20opinion%20on%20drug%20delivery&rft.au=Diab,%20Roudayna&rft.date=2007-09-01&rft.volume=4&rft.issue=5&rft.spage=513&rft.epage=531&rft.pages=513-531&rft.issn=1742-5247&rft.eissn=1744-7593&rft_id=info:doi/10.1517/17425247.4.5.513&rft_dat=%3Cproquest_hal_p%3E20350481%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20350481&rft_id=info:pmid/17880274&rfr_iscdi=true |